Q-Med and Oceana takes major step towards SOLESTA(TM)

Q-Med AB and Oceana Therapeutics, Inc. today announced that the
SOLESTA(TM) pivotal study succeded in meeting both primary endpoints
for the treatment of fecal incontinence.

Q-Med AB and Oceana Therapeutics, Inc. intend to submit a PMA
application to the FDA during the first quarter of 2010 based on the
results of this study.

- This study is the ultimate result of years of hard work as we
developed a product using our minimally invasive technology," said
Bengt Ågerup, Q-Med's President and CEO, and inventor of the
NASHA(TM) technology.  - It is with great pride that together with
our partner, Oceana Therapeutics, we can move forward with the FDA
approval process and work towards bringing SOLESTA(TM) into clinical
practice.

Fecal incontinence is a significant problem for many adults as it
relates to the loss of voluntary control of stool, or bowel
movements.   It affects about 2 percent of the general population.
Both men and women suffer from this problem, though it is more common
in women because of injury during childbirth. The condition can have
devastating effects on a patient's quality of life and psychological
well being as many people resort to altering their social and
physical activities, even their employment, to cope with the problem.


-We are extremely encouraged by the positive results from this
pivotal trial. We believe SOLESTA has the potential to make a
significant contribution in fulfilling an unmet medial need in the
management of fecal incontinence and will therefore be a great
addition to Oceana's product portfolio, said John Spitznagel,
Chairman and CEO, Oceana Therapeutics, Inc.  - These findings also
mark an important milestone for the partnership between Q-Med AB and
Oceana as the study outcomes will allow us to file for approval with
the FDA in the first quarter of 2010.
Oceana's President and COO, David S. Tierney, M.D. added, - While
SOLESTA is already available in Europe, we are confident that the
publication of the study will enhance the adoption of this important
treatment among the European professional community to help patients
suffering from this condition.

About the Study
The Investigational Device Exemption Study was a randomized, subject
and evaluator blinded, controlled, multi-center study designed to
evaluate the efficacy and safety of SOLESTA  for the treatment of
fecal incontinence. More than 200 patients suffering from fecal
incontinence were included in 13 study sites throughout the United
States and Europe.  Primary endpoints of the study looked at the
efficacy of both groups at six months as well as evaluated the
durability of response in the SOLESTA treatment group at 12 months.

About SOLESTA(TM)
SOLESTA is approved for use in Europe and Canada as an injectable
treatment for fecal incontinence. SOLESTA is a biocompatible
substance composed of stabilized hyaluronic acid, including
dextranomer, manufactured according to Q-Med AB's patented
technology, NASHA(TM).  The treatment is a minimally invasive,
in-office procedure. SOLESTA was developed in 2004 by Q-Med AB in
Sweden. Oceana Therapeutics acquired the global rights to market and
sell SOLESTA in June 2009.

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 70 974 9025

Cindy Wong, Chief Medical Officer, Head of Medical Affairs
Tel: +46 73 387 1450

Per Langö, Senior Director Corporate Development
Tel: +46 73 387 1521

About Oceana Therapeutics, Inc.
Oceana Therapeutics was founded in 2008 by a team of seasoned
healthcare executives and is privately held. The Company is committed
to acquiring and maximizing the potential of approved and late-stage
development medical devices and specialty therapeutics, redefining
the way illnesses are treated. Oceana's goal is to enable physicians
to prescribe drugs and utilize devices that are tailored for the
patient's disease - offering Optimal Outcomes - as well as the added
economic benefit of limiting or eliminating hospitalization or
reducing demand for surgery or emergency care. This approach balances
both the patient's wellness needs and the physician's goal of
providing outstanding patient care while efficiently balancing time
and economic management constraints. For additional information about
Oceana Therapeutics, visit the Company's website at
www.oceanathera.com.


Q-Med AB is a medical device company. The company develops,
manufactures, markets, and sells primarily medical implants. The
majority of the products are based on the company's patented
technology, NASHA(TM), for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for
filling lines and folds, contouring and creating volume in the face,
Macrolane(TM) for body contouring, Durolane(TM) for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment
of vesicoureteral reflux, VUR, (a malformation of the urinary
bladder) in children, and Solesta(TM) for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries
or distributors in over 70 countries. Q-Med today has about 650
coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid
Cap segment of the NASDAQ OMX Nordic.

   Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden.
               Corporate identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com.
                         Web: www.q-med.com.